Stephens Inc. AR Acquires 3,055 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Stephens Inc. AR lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 126.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,463 shares of the medical research company's stock after buying an additional 3,055 shares during the quarter. Stephens Inc. AR's holdings in Charles River Laboratories International were worth $1,076,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Trust Direct Indexing L.P. acquired a new stake in shares of Charles River Laboratories International in the 1st quarter worth approximately $211,000. Norden Group LLC grew its holdings in Charles River Laboratories International by 60.3% in the first quarter. Norden Group LLC now owns 1,836 shares of the medical research company's stock valued at $497,000 after purchasing an additional 691 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Charles River Laboratories International by 45.3% in the first quarter. BNP Paribas Financial Markets now owns 67,148 shares of the medical research company's stock valued at $18,194,000 after buying an additional 20,941 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Charles River Laboratories International by 5.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 46,006 shares of the medical research company's stock worth $12,465,000 after buying an additional 2,300 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Charles River Laboratories International by 23.9% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,986 shares of the medical research company's stock worth $538,000 after buying an additional 383 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Robert W. Baird cut their price target on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a report on Friday, September 20th. UBS Group decreased their price target on shares of Charles River Laboratories International from $290.00 to $240.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. The Goldman Sachs Group decreased their price target on Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating for the company in a report on Thursday, August 8th. TD Cowen cut their target price on Charles River Laboratories International from $228.00 to $203.00 and set a "hold" rating on the stock in a research report on Monday, August 12th. Finally, JPMorgan Chase & Co. lowered Charles River Laboratories International from an "overweight" rating to a "neutral" rating and dropped their price target for the company from $270.00 to $205.00 in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $209.00.

Charles River Laboratories International Stock Up 3.4 %

NYSE:CRL traded up $6.20 on Tuesday, hitting $188.68. 997,710 shares of the company's stock traded hands, compared to its average volume of 607,041. The firm has a 50-day moving average price of $193.28 and a 200-day moving average price of $208.83. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.74 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 6.20 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $166.87 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.39 by $0.41. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback plan on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).